Table 2 Patient demographics of the FMF cohort, CGD patients, and healthy controls (HC) serving for granulocyte isolation and analyses

Gender (female/male)

8/7

2/3

4/6

Mutations

11× M694V/M694V

2× M694I/M694I

1× V726A/M680I

1× M680I/M694V

3× CYBB heterozygous, 2× NCF4 homozygous

n/a

Age in years

11 (6–13)

17.5 (7.5–18)

39 (29.3–48)

Medication

13× colchicine, 2× colchicine + canakinumab

Antibiotic and antimycotic prophylaxis

n/a

CRP (mg/dl)

0.2 (0.2–1)

<0.5

n/a

SAA (mg/l)

4.2 (2–38.7)

n/a

n/a

ESR (mm/h)

7 (5–15)

n/a

n/a

Leukocytes (per nl)

6.09 (5.38–8.34)

6.91

n/a

S10012 (ng/ml)

56 (23–1108)

56 (32–71)

n/a

S100A8/A9 (ng/ml)

3380 (2320–43,480)

1540

n/a